Argenica Therapeutics Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Liz Dallimore
Chief Executive Officer (CEO)
AU$424.2k
Compensación total
| Porcentaje del salario del CEO | 67.8% |
| Permanencia del CEO | 2.4yrs |
| Participación del CEO | 1.3% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 2.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans
Sep 23
Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth
Jan 12Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business
Jul 20Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business
Apr 20We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate
Nov 30Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans
Aug 12Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation
Apr 29Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation
Dec 30We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate
Sep 16Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | AU$424k | AU$288k | -AU$5m |
| Mar 31 2024 | n/a | n/a | -AU$5m |
| Dec 31 2023 | n/a | n/a | -AU$5m |
| Sep 30 2023 | n/a | n/a | -AU$5m |
| Jun 30 2023 | AU$675k | AU$250k | -AU$5m |
| Mar 31 2023 | n/a | n/a | -AU$4m |
| Dec 31 2022 | n/a | n/a | -AU$4m |
| Sep 30 2022 | n/a | n/a | -AU$4m |
| Jun 30 2022 | AU$337k | AU$228k | -AU$4m |
| Mar 31 2022 | n/a | n/a | -AU$3m |
| Dec 31 2021 | n/a | n/a | -AU$3m |
| Sep 30 2021 | n/a | n/a | -AU$2m |
| Jun 30 2021 | AU$145k | AU$31k | -AU$1m |
Compensación vs. Mercado: La compensación total ($USD289.37K) de Liz está en línea con el promedio de empresas de tamaño similar en el mercado Australian ($USD303.76K).
Compensación vs. Ingresos: La compensación de Liz ha sido consistente con los resultados de la empresa en el último año.
CEO
Liz Dallimore
2.4yrs
Permanencia
AU$424,246
Compensación
Dr. Liz Dallimore (B. Sc. (Hons), MBA, PhD, GAICD) serves as Chief Executive Officer of Argenica Therapeutics Limited ands serves as its Managing Director and Director since April 4, 2022. She is a researc...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, MD & Director | 2.4yrs | AU$424.25k | 1.29% A$ 1.2m | |
| Non-Executive Chairman | less than a year | AU$102.58k | sin datos | |
| Member of Clinical Advisory Committee | no data | sin datos | sin datos | |
| Independent Non-Executive Director | 3.7yrs | AU$44.40k | 0.63% A$ 576.1k | |
| Independent Non-Executive Director | 3.8yrs | AU$44.40k | 0.35% A$ 316.9k | |
| Non-Executive Director | no data | sin datos | 0.020% A$ 17.9k | |
| Member of Clinical Advisory Committee | no data | sin datos | sin datos | |
| Member of Clinical Advisory Committee | no data | sin datos | sin datos | |
| Chairman of Clinical Advisory Committee | no data | sin datos | sin datos | |
| Member of Clinical Advisory Committee | 2.2yrs | sin datos | sin datos | |
| Non-Executive Director | no data | sin datos | sin datos |
2.2yrs
Permanencia media
Junta con experiencia: La junta directiva de AGN no se considera experimentada (2.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.